Abstract Library

#3335 Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

Introduction: Currently, there is minimal published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited response for lower grade 1-2 NETs, but the optimal therapy for metastatic G3 NETs is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McGarrah P

Authors: McGarrah P, Liu A, Hobday T, Starr J, Kendi A,

Keywords: somatostatin analogues, lanreotide, octreotide, well-differentiated grade 3 neuroendocrine tumor, G3net, G3nen,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3254 COVID-19 in patients with neuroendocrine tumors (NETs): The Mayo Clinic experience

Introduction: Coronavirus Disease 2019 (COVID-19) has been associated with increased morbidity and mortality in cancer patients. NETs are rare and there is paucity of data about COVID-19 outcomes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Rakshit S

Authors: Rakshit S, Lee K, Kendi A, Sonbol M, Starr J,

Keywords: neuroendocrine tumor, covid-19, outcomes, mortality,

#3239 Prevalence and presentation of Cushing and carcinoid syndromes in patients with non-metastatic primary lung neuroendocrine tumors (NETs)

Introduction: Carcinoid syndrome and Cushing syndrome are rare in non-metastatic lung NETs. In patients with small bowel NETs, carcinoid syndrome is usually associated with metastatic disease. In lung NETs, biologically active substances may be released directly into systemic circulation without inactivation in the liver or lungs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Lee K, Rakshit S, Kendi A, Wigle D, Leventakos K,

Keywords: lung neuroendocrine, carcinoid, cushing,

#3228 Sensitivity of 68Ga-DOTATATE PET in detecting primary tumor and nodal metastases in surgically resected lung carcinoids

Introduction: 68Ga-DOTATATE positron emission tomography (PET) is increasingly employed in staging of lung carcinoids prior to surgery.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Rakshit S

Authors: Rakshit S, Lee K, Kendi A, Wigle D, Leventakos K,

Keywords: DOTATATE PET, staging, carcinoid,